Full Text View
Tabular View
No Study Results Posted
Related Studies
Gemcitabine in Treating Patients With Recurrent or Refractory Bladder Cancer
This study has been completed.
Study NCT00014287   Information provided by National Cancer Institute (NCI)
First Received: April 10, 2001   Last Updated: July 23, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Bladder Cancer
Additional conditions recognized in this trial
Urinary Bladder Neoplasms
More general conditions related to this trial
Neoplasms
Neoplasms by Site
Urinary Bladder Diseases
Urogenital Neoplasms
Urologic Diseases
Urologic Neoplasms
Interventions listed in this trial
gemcitabine hydrochloride
Additional drug interventions recognized in this trial
Gemcitabine
More general drug interventions related to this trial
Anti-Infective Agents
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antiviral Agents
Enzyme Inhibitors
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Radiation-Sensitizing Agents
Therapeutic Uses
Sponsors listed in this trial
UPMC Cancer Centers
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services